Sunridge Receives Marketing Progress in China

FOUNTAIN HILLS, Ariz., Nov. 22, 2010 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ), receives progress update on Pneumatic Trabeculoplasty (PNT) in China.  Beijing Vision World Trading, Sunridge's exclusive distributor in China, reports the following activities as part of their marketing rollout plans for PNT.

A spokesperson for Beijing Vision has outlined their progress as follows. Since receiving SFDA approval earlier this year, they have attended provincial conferences in Xinjiang, Shandong and Shanxi and held training sessions in Northeast China, Hubei, Hunan, and Jiangsu.  Also, they held a promotional seminar exclusively for PNT, which was attended by over 200 experts and 30 sub distributors from all over China. This seminar resulted in the signing of top sub distributors which combined have the ability to serve all of China.

Most recently, Beijing Vision attended the National Ophthalmic Conference, and held a seminar exclusively for PNT.  Several top experts spoke about PNT to an audience of over 6000 ophthalmic doctors from all over China.

As part of their humanitarian effort to give back to the people of China, Beijing Vision is working with the China Disabled Person's Federation and the State Council Leading Group Office of Poverty Alleviation and Development to donate PNT equipment and rings for the treatment of disabled people in less developed areas.

"I am very happy about how well Beijing Vision is moving forward with their marketing program," states G. Richard Smith, CEO of Sunridge.  "Between their professionalism and their humanitarian efforts we could not ask for a better company to represent us in the Chinese market.  They have gone to great lengths to disseminate information about PNT and its benefits to hospitals, clinics, independent doctors and patients alike.  It's through an education process like this that will insure PNT's usefulness as a treatment for glaucoma in China."  

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).

SOURCE Sunridge International